HGH Fragment 176-191 — an unmodified 16-amino acid sequence corresponding to residues 176-191 of the human growth hormone — has not been studied in humans [1]. This means that much of what the title of this article suggests, such as established dosage ranges, known pharmacokinetics or specific cycle lengths, does not actually exist in the published literature for this specific compound. Where the outline of commonly searched questions assumes data that does not exist, this article states this directly, rather than filling the gap with numbers taken from commercial sources or vendors. This article reports exclusively research parameters and study data appearing in peer-reviewed and regulatory sources reviewed for this series. It does not provide personal dosage recommendations, reconstitution instructions or guidance on use of any kind.
Dosage ranges reported in studies
Based on the sources gathered for this series, only one study directly tested the unmodified hGH Fragment 176-191 sequence in a living model. It used a single dose level rather than a range. In this 1978 study, researchers administered synthetic C-terminal fragments of human growth hormone, including hGH 176-191, to normal rats at a dose of 5 nmol/kg of body weight. This was given as a single intravenous injection to observe the effects on blood glucose and plasma insulin [2].
No published studies identified in this series report a dosing range of „250mcg–500mcg” for humans, nor 5mg/10mg/6mg vial concentrations, as tested clinical or pre-clinical dose levels for this specific compound. Such figures, which circulate widely in commercial vendor offerings, reflect product packaging and marketing conventions rather than doses established by published research. This article does not repeat these numbers as if they were data derived from research, because no such study exists in the reviewed sources.
Methods of administration documented in research
Injection route. The only identified study of the unmodified fragment used a single intravenous injection in rats [2]. A separate 2022 study used the peptide as a component incorporated into chitosan nanoparticles, at a concentration of 50 nm/ml, alongside doxorubicin. This was part of an experimental anticancer drug delivery system tested in vitro against breast cancer cells. This is a specialised laboratory nanoparticle formulation, rather than a standalone injection protocol. The study did not test the peptide itself in a living organism [3].
Nasal spray formulations. No peer-reviewed study identified in this series tested a nasal spray formulation of unmodified HGH Fragment 176-191. Nasal spray products associated with this compound name in commercial contexts are not supported by any studies identified here.
Methods of reconstitution. No published study describes a reconstitution protocol, that is, mixing the lyophilised peptide with a solvent, for the unmodified fragment. This is because no human injection study or independent animal dosing outside of a single 1978 rat experiment has been identified. The „preparation” in the 2022 nanoparticle study was a nanoparticle synthesis process using ionic gelation with chitosan and gum arabic—not a reconstitution method relevant to self-administration of the peptide [3].
Pharmacokinetics: half-life and duration of action
No pharmacokinetic study identified in this series — meaning no study measuring absorption, distribution, half-life, or clearance — exists for unmodified HGH Fragment 176-191. Specifically, no half-life figure (such as „1-2 hours”) for this exact compound was found in the sources gathered here. Any such figure seen elsewhere should be treated with caution, as it is not traceable to a peer-reviewed pharmacokinetic study of this fragment in the literature reviewed for this article.
For context, full-length hGH itself has been pharmacokinetically investigated in other studies. This includes research into its molecular isoforms, such as the 20-kDa and 22-kDa forms, and their differing behaviour in circulation [4], [5]. Pharmacokinetic data for the full hormone do not, however, translate to the small C-terminal fragment derived from it, and no source reviewed here makes this comparison with supporting data.
Duration of tests/trials
The only identified study testing the unmodified fragment directly used a single acute dose. Effects were measured over the course of that single experiment rather than through repeated dosing or an extended „cycle” [2].
No multi-week, multi-month, or six-month safety study of unmodified HGH Fragment 176-191 has been identified in either humans or animals in the sources reviewed for this series. Where data on „cycle length” or study duration actually exist in the broader literature—for example, in the 14-day chronic mouse studies and 19-day rat studies of the related compound AOD-9604 discussed in Article 2—such data apply to a structurally distinct compound, not to the unmodified fragment [6], [7].
Reported side effects and safety signals
Adverse events reported in the literature. The only significant study showed that hGH 176-191, along with several related C-terminal fragments (172-191, 177-191, 178-191), induced a short-term increase in blood glucose and a more sustained increase in plasma insulin in rats following a single dose. At the same dose, hGH fragments containing the 178-191 sequence significantly reduced insulin sensitivity in intravenous insulin tolerance tests [2]. These findings describe effects on glucose and insulin regulation in rats — not the general side effect profile in humans — and should not be extrapolated to humans.
Data gaps. No human study of any kind, no long-term animal study, and no dedicated human or animal safety study of unmodified HGH Fragment 176-191 exists in the sources reviewed for this series.
A broader 2026 narrative review on performance-enhancing peptides affecting the growth hormone/IGF-1 axis, which refers to AOD9604 (hGH 176-191) as a single compound within a broader unregulated category, notes that adverse effects reported for this general class of compounds include endocrine and metabolic disorders, fluid retention, musculoskeletal symptoms and injection site reactions [8]. This reflects the entire class of compounds broadly, largely derived from self-administration reports and pharmacological reasoning regarding related peptides — rather than confirmed data specific to the unmodified 176-191 fragment [8].
Why is there no standardised, approved dosage
HGH Fragment 176-191 is not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any equivalent regulatory body as a labelled pharmaceutical product.
Approved medicines carry standardised, regulator-reviewed dosage information because this information is generated through a formal clinical trial process. This includes dose-finding studies (Phase I), monitoring of efficacy and side effects (Phase II/III), and regulatory review of the resulting data. Because no such trial process has taken place for this compound, no standardised, approved dosage exists, and none can be accurately reported. Any language of „typical dosage” attributed to this compound in commercial or informal sources reflects research or vendor convention, rather than medical guidance, and is not equivalent to approved drug label dosing instructions.
FAQs
What doses were tested in the trials? Only one dose level in one study is documented for the unmodified fragment: 5 nmol/kg body weight, administered as a single intravenous dose in rats [2]. No human dose of any kind has been tested in the published studies identified in this series.
How long do the effects last, according to pharmacokinetic data? This cannot be answered as no pharmacokinetic study (measuring the half-life or duration of action) of unmodified HGH Fragment 176-191 has been identified in the reviewed sources. The only animal study describes its glucose-raising effect as „short-acting” and its insulin-raising effect as „more sustained”, but did not report specific half-life figures [2].
What was the minimum effective dose in the cited studies? A 1978 study tested a single dose level (5 nmol/kg) rather than a dose-range design. No minimum effective dose can therefore be identified from it [2]. No other study identified in this series established a dose-response relationship for this compound.
Is there a best time to take it, based on trial protocols? No study identified in this series reports a specific time-of-day or nutritional state protocol for the administration of unmodified HGH Fragment 176-191. The only relevant study does not specify fasting or postprandial conditions in a way that would support a recommendation for the „best time” [2].
Disclaimer
HGH Fragment 176-191 is not approved by the US Food and Drug Administration, the European Medicines Agency or any equivalent regulatory body for human medical use, and no standardised, approved dosage exists for it. Published studies identified for this compound are limited to a single animal study from 1978 measuring glucose and insulin effects and an in vitro anti-cancer nanoparticle study from 2022. No human trials, no dedicated pharmacokinetic studies and no long-term safety studies of this specific compound have been identified. This article reports solely on what has been published and explicitly states where no data exist; it does not provide dosage figures, reconstitution instructions or administration guidance for personal use. This content is for general educational and informational purposes only, does not constitute medical advice and should not be used as the basis for a decision to use, buy or administer this or any peptide.
References
[1] Wikipedia contributors. (2025, December 30). HGH Fragment 176–191. Wikipedia, The Free Encyclopaedia. https://en.wikipedia.org/wiki/HGH_Fragment_176%E2%80%93191
[2] Ng, F. M., & Bornstein, J. (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. American Journal of Physiology, 234(5), E521–E526. https://doi.org/10.1152/ajpendo.1978.234.5.E521
[3] Habibullah, M. M., Mohan, S., Syed, N. K., Makeen, H. A., Jamal, Q. M. S., Alothaid, H., Bantun, F., Alhazmi, A., Hakamy, A., Kaabi, Y. A., Samlan, G., Lohani, M., Thangavel, N., & Al-Kasim, M. A. (2022). Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug Design, Development and Therapy, 16, 1963–1974. https://doi.org/10.2147/DDDT.S367586
[4] Hashimoto, Y., Kamioka, T., Hosaka, M., Mabuchi, K., Mizuchi, A., Shimazaki, Y., Tsunoo, M., & Tanaka, T. (2000). Exogenous 20K growth hormone (GH) suppresses endogenous 22K GH secretion in normal men. The Journal of Clinical Endocrinology & Metabolism, 85(2), 601–606. https://doi.org/10.1210/jcem.85.2.6377
[5] Baumann, G., MacCart, J. G., & Amburn, K. (1983). The molecular nature of circulating growth hormone in normal and acromegalic man: Evidence for a principal and minor monomeric forms. The Journal of Clinical Endocrinology & Metabolism, 56(5), 946–952. https://doi.org/10.1210/jcem-56-5-946
[6] Heffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., & Ng, F. M. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189. https://doi.org/10.1210/endo.142.12.8522
[7] Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278. https://doi.org/10.1159/000053183
[8] Dominikowski, A., Rękoś, Z., Olejarz, M., Szczepanek-Parulska, E., Domin, R., & Ruchała, M. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: Bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, 1822475. https://doi.org/10.3389/fendo.2026.1822475